Current management of ophthalmic zoster.

Most ophthalmic zoster occurs in healthy people and ocular complications occur in 50%. The mainstay of ocular therapy is topical steroid, but careful follow-up and withdrawal are essential. The place of systemic steroid therapy and acyclovir in immunocompetent patients with zoster is uncertain.